123 related articles for article (PubMed ID: 17679484)
41. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas.
Erickson LC; Bradley MO; Ducore JM; Ewig RA; Kohn KW
Proc Natl Acad Sci U S A; 1980 Jan; 77(1):467-71. PubMed ID: 6928639
[TBL] [Abstract][Full Text] [Related]
42. Management of metastatic melanoma.
Tawbi HA; Kirkwood JM
Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
[TBL] [Abstract][Full Text] [Related]
43. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
44. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
[TBL] [Abstract][Full Text] [Related]
45. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
46. [Analysis of MGMT methylation with the therascreen(®) MGMT Pyro(®) Kit (Qiagen). A method verification].
Luquain A; Magnin S; Guenat D; Prétet JL; Viennet G; Valmary-Degano S; Mougin C
Ann Biol Clin (Paris); 2015; 73(6):665-70. PubMed ID: 26635047
[TBL] [Abstract][Full Text] [Related]
47. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
48. Antiproliferative Activity of a New Nitrosyl Iron Complex with Cysteamine in Human Tumor Cells In Vitro.
Zhukova OS; Smirnova ZS; Chikileva IO; Kiselevskii MV
Bull Exp Biol Med; 2017 Feb; 162(4):583-588. PubMed ID: 28239795
[TBL] [Abstract][Full Text] [Related]
49. Chemotherapy resistance abrogation in metastatic melanoma.
Tawbi HA; Buch SC
Clin Adv Hematol Oncol; 2010 Apr; 8(4):259-66. PubMed ID: 20505649
[TBL] [Abstract][Full Text] [Related]
50. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
51. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
52. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML
Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398
[TBL] [Abstract][Full Text] [Related]
53. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
54. Regulation of DNA Alkylation Damage Repair: Lessons and Therapeutic Opportunities.
Soll JM; Sobol RW; Mosammaparast N
Trends Biochem Sci; 2017 Mar; 42(3):206-218. PubMed ID: 27816326
[TBL] [Abstract][Full Text] [Related]
55. [Combi-molecules: a global approach towards better chemoselectivity and chemosensitivity].
Matheson S; Qiu Q; Brahimi F; Dudouit F; Banerjee R; Rachid Z; Jean-Claude BJ
Bull Cancer; 2004 Dec; 91(12):911-5. PubMed ID: 15634632
[TBL] [Abstract][Full Text] [Related]
56. Investigation of J-shaped dose-responses induced by exposure to the alkylating agent N-methyl-N-nitrosourea.
Chapman KE; Hoffmann GR; Doak SH; Jenkins GJS
Mutat Res Genet Toxicol Environ Mutagen; 2017 Jul; 819():38-46. PubMed ID: 28622829
[TBL] [Abstract][Full Text] [Related]
57. Theoretical study of some nitrososulfamide compounds with antitumor activity.
Djameleddine K; Soumeya S; Fatiha M
Molecules; 2004 Sep; 9(10):883-93. PubMed ID: 18007489
[TBL] [Abstract][Full Text] [Related]
58. The new mindset for embracing precision medicine: Developing new approaches for exploring diseases.
Lin MC; Iqbal U; Jack Li YC
Comput Methods Programs Biomed; 2017 Mar; 140():A1. PubMed ID: 28254095
[No Abstract] [Full Text] [Related]
59. Cancer therapy. Targeting the poison within.
Smits VA; Gillespie DA
Cell Cycle; 2014; 13(15):2330-3. PubMed ID: 25483183
[TBL] [Abstract][Full Text] [Related]
60. TCNU: a ray of hope for designer nitrosoureas?
Workman P
Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1823-8. PubMed ID: 3325292
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
